New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The break­through ther­a­py des­ig­na­tion Pfiz­er and Mer­ck KGaA notched for Baven­cio in blad­der can­cer has quick­ly paved way for a full ap­proval.

The PD-L1 drug is now sanc­tioned as a first-line main­te­nance treat­ment for pa­tients with lo­cal­ly ad­vanced or metasta­t­ic urothe­lial car­ci­no­ma, ap­plic­a­ble in cas­es where can­cer hasn’t pro­gressed af­ter plat­inum-con­tain­ing chemother­a­py.

Pet­ros Gri­vas, the prin­ci­pal in­ves­ti­ga­tor of the sup­port­ing Phase III JAVELIN Blad­der 100, called the ap­proval “one of the most sig­nif­i­cant ad­vances in the treat­ment par­a­digm in this set­ting in 30 years.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.